This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción O2T
IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Competidores de IVERIC bio, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.00 |
| 52 Week High | US$36.20 |
| 52 Week Low | US$9.37 |
| Beta | 1.1 |
| 1 Month Change | 2.27% |
| 3 Month Change | 44.00% |
| 1 Year Change | 226.44% |
| 3 Year Change | n/a |
| 5 Year Change | 1,521.62% |
| Change since IPO | 68.22% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| O2T | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | -0.6% | 1.6% | -1.4% |
| 1Y | 226.4% | -21.6% | 2.2% |
Rentabilidad vs. Industria: O2T exceeded the German Biotechs industry which returned -6.5% over the past year.
Rentabilidad vs. Mercado: O2T exceeded the German Market which returned 7.1% over the past year.
Volatilidad de los precios
| O2T volatility | |
|---|---|
| O2T Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Precio estable de las acciones: O2T's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: O2T's weekly volatility has decreased from 12% to 6% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2007 | 163 | Glenn Sblendorio | ivericbio.com |
Resumen de fundamentos de IVERIC bio, Inc.
| Estadísticas fundamentales de O2T | |
|---|---|
| Capitalización bursátil | €5.01b |
| Beneficios(TTM) | -€202.55m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-24.7x
Ratio precio-beneficio (PE)¿Está O2T sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de O2T | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$136.54m |
| Beneficio bruto | -US$136.54m |
| Otros gastos | US$86.37m |
| Beneficios | -US$222.90m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.62 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 20.3% |
¿Cómo se ha desempeñado O2T a largo plazo?
Ver rendimiento histórico y comparativa